Antisense Therapeutics Limited

Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc., an established leader in antisense drug development.

The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne Muscular Dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.

Antisense is committed to providing shareholders, potential investors, and the public with a transparent view of efforts toward fulfilling thier purpose: Breakthroughs that change patients’ lives. To that end, the company’s annual reports detail the strategic development, operations, and financial condition of the business.

Vision & mission

To bring life changing innovative medicines to patients in need and to add value for all stakeholders through actively exercising our beliefs of honesty, integrity and collaboration. Antisense serves the needs of our patients and stakeholders to the best of our combined abilities.

Company news

We help investors gain insights into your company through high quality research reports.

We provide a full suite of corporate access services.

 
 
 
Corporate Connect Research

Level 7, 7 Macquarie Place
Sydney NSW 2000
Australia

Email us

Contact us

14 + 9 =